Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Intrinsic Microenvironment-Dependent Potentiation of Antibodies for Cancer Therapy

Project description

Leveraging the tumour microenvironment to increase immunotherapy’s toxicity

Immunotherapy has great potential in treating some kinds of cancers and immunoglobulin G (IgG) plays an important role. The ERC-funded IMPACT project aims to use a common tumour side effect to increase the proinflammatory and cytotoxic efficacy of engineered IgG against tumours. There is strong evidence that tumours, and particularly malignant ones, can cause local haemorrhaging. In addition, haeme, a component of haemoglobin in red blood cells, can trigger oligomerisation of engineered IgG molecules, increasing their ability to activate the complement system and induce killing of cancer cells. IMPACT will investigate whether locally released haeme and haemoproteins at tumour sites can be leveraged to locally potentiate immunotherapy’s toxic effects on tumours.

Objective

The principal goal of this proof-of-concept study is to explore the feasibility of a cofactor-induced oligomerisation of IgG to potentiate the therapeutic efficacy of anti-cancer antibodies targeting the tumour site. Our idea is based on two phenomena: Firstly, in our previous studies on the interaction of heme with therapeutic antibodies we found that the interaction of Trastuzumab with heme results in the formation of well-organized oligomers through Fab-Fab interactions of two IgG molecules. These species were considerably more potent in activating the complement system and inducing killing of cancer cells. Importantly, we were able to transfer the potential for oligomeriszation mediated by heme on two unrelated monoclonal antibodies used in clinical practice, thus providing strong evidence of the feasibility of the engineering effort and the utility of its application for broad range of IgG molecules. Secondly, there is strong evidence in the literature about the ability of tumours (especially malignant) to provoke haemorrhages. Based on these two phenomena, we formulated our working hypothesis that the locally released heme and hemoproteins at tumour sites can be harnessed as trigger of oligomerization of engineered IgG molecules, thus increasing their pro-inflammatory and cytotoxic activities due to aggregation of the Fc portion in close proximity. This will result in higher antibody avidity, more efficient cross-linking of Fc-gamma receptors, better recruitment of complement proteins (C1q) and, hence, a stronger activation of the immune effector cells and the classical pathway of complement system on the surface of cancer cells. Successful accomplishment of this project will have considerable societal impact due to clinical and social significance of cancer.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 150 000,00
Address
RUE DE TOLBIAC 101
75654 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)